Skip to content

Advertisement

  • Research
  • Open Access

Role of protease-activated receptor-2 on cell death and DNA fragmentation in Helicobacter pylori-infected gastric epithelial cells

Journal of Translational Medicine20108:85

https://doi.org/10.1186/1479-5876-8-85

©  Lim and Kim; licensee BioMed Central Ltd. 2010

  • Received: 15 January 2010
  • Accepted: 16 September 2010
  • Published:

Abstract

Background

Helicobacter pylori (H. pylori) infection is associated with chronic gastritis, peptic ulceration and gastric carcinoma. Protease-activated receptor-2 (PAR-2), which is activated by trypsin, induced the activation of mitogen-activated protein kinases (MAPK), cell proliferation and apoptosis in several cells. Previously, we found that H. pylori induces the expression of PAR-2, which mediates the expression of adhesion molecules integrins in gastric epithelial cells. In the present study, the role of PAR-2 on H. pylori-induced cell death was investigated by determining cell viability, DNA fragmentation, and the activation of MAPK in gastric epithelial AGS cells.

Methods

AGS cells were cultured in the presence of H. pylori transfected with PAR-2 antisense (AS) oligonucleotide (ODN) or treated with a soybean trypsin inhibitor (SBTI). Viable cells and DNA fragmentation were determined by trypan blue exclusion assay and the amount of oligonucleosome-bound DNA, respectively. The activation of MAPK such as extracellular signal-regulated kinases (ERK), p38, and c-Jun N-terminal kinases (JNK), was assessed by Western blotting for phospho-specific forms of MAPK.

Results

H. pylori-induced cell death and DNA fragmentation augmented in the cells transfected with PAR-2 AS ODN or treated with SBTI. The activation of MAPK, induced by H. pylori, were suppressed by transfection with PAR-2 AS ODN or treatment with SBTI.

Conclusion

PAR-2, whose expression is induced by H. pylori, may prevent cell death and DNA fragmentation with the activation of MAPK in gastric epithelial cells.

Keywords

  • Pylorus Infection
  • cagA
  • Gastric Epithelial Cell
  • Becton Dickinson Microbiology System
  • Human Gastric Epithelial Cell Line

Background

Helicobacter pylori (H. pylori) has been shown to be an important pathogen of gastroduodenal inflammation and gastric carcinogenesis [1, 2]. H. pylori infection increases epithelial apoptosis in gastric mucosa, which may play an important role in gastric carcinogenesis [3]. H. pylori-induced apoptosis may stimulate compensatory hyperproliferation which results in potential preneoplastic changes in chronic H. pylori infection [4–6]. H. pylori -induced apoptosis has been shown in gastric epithelial cells [7, 8] as well as infected gastric tissues [6, 9, 10]. However, the apoptotic mechanism induced by H. pylori infection has not been fully elucidated.

H. pylori activates three main groups of mitogen-activated protein kinases (MAPKs), i.e., the extracellular signal-regulated kinases 1 and 2 (ERK1/2), p38 MAPKs, and c-Jun N-terminal kinases [11, 12]. Recently, it was shown that inhibition of the ERK1/2 pathway augmented H. pylori-induced apoptosis in gastric epithelial cells [13], demonstrating the possible involvement of MAPK in gastric apoptosis.

Proteinase-activated receptors (PARs), a family of G protein-coupled seven-trans-membrane domain receptors, mediate a variety of intracellular signaling and subsequent cellular events caused by specific extracellular proteinases [14, 15]. The family of PARs currently includes four members: PAR-1, PAR-2, PAR-3 and PAR4. The coagulant protease thrombin is the physiological activator of PAR-1, PAR-3, and PAR-4. PAR-2 is activated by multiple trypsin-like serine proteases including trypsin, tryptase and coagulation protease upstream of thrombin. Activation of PAR-2 triggers the activation of multiple signaling pathways, including MAPK cascades in distinct cell types [16, 17]. PAR-2 is involved in cell proliferation and apoptosis in several cell types [18, 19]. Recent data suggest that activation of PAR-2 rescued cells from apoptosis via activation of MAPKs [20]. We previously demonstrated that H. pylori induces the activation and expression of PAR-2 in gastric epithelial cells [21, 22]. These results demonstrate the possible relations of the expression of PAR-2, the activation of MAPK, and apoptosis in H. pylori-infected gastric epithelial cells. The present study aims to investigate whether H. pylori-induced apoptotic cell death is related to the expression of PAR-2 and the activation of MAPK in gastric epithelial cells.

Methods

Bacterial strain

An H. pylori strain used in the present study is HP99 isolated form Korean patients and identified as cagA+, vacA+ strain [12]. HP99 is kindly provided from Dr. H.C. Jung (Seoul National University College of Medicine, Seoul, Korea). These bacteria were inoculated onto chocolate agar plates (Becton Dickinson Microbiology Systems, Cockeysville, MD, USA) at 37°C under microaerophilic conditions using an anaerobic chamber (BBL Campy Pouchs System, Becton Dickinson Microbiology Systems).

Cell culture and H. pylori stimulation

A human gastric epithelial cell line AGS (gastric adenocarcinoma, ATCC CRL 1739) was obtained from the American Type Culture Collection (Rockville, MD, USA). The cells were grown in complete medium, consisting of RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin (Sigma, St. Louis, MO, USA). AGS cells were seeded and cultured to reach 80% confluency. Prior to the stimulation, each dish was washed twice with fresh cell culture medium containing no antibiotics. H. pylori was harvested, washed with phosphate buffered saline (PBS), and then resuspended into antibiotic-free cell culture medium. H. pylori was added to AGS cells at bacterium/cell ratio of 150:1 or 300:1, and cultured for the indicated time periods.

Experimental protocol

To investigate the relations of apoptotic cell death, the expression of PAR-2, and the activation of MAPK in H. pylori-infected gastric epithelial cells, cell viability and DNA fragmentation were determined in the cells transfected with PAR-2 AS ODN or S ODN or treated with soybean trypsin inhibitor (SBTI; 0.2 μM, 0.5 μM) and cultured in the presence of H. pylori at bacterium/cell ratio of 150:1 (cell viability) or 300:1 (cell viability, DNA fragmentation) for 24 hours. For the activation of MAPK, AGS cells were transfected with PAR-2 AS ODN or S ODN or treated with soybean trypsin inhibitor (SBTI; 0.2 μM, 0.5 μM) and cultured in the presence of H. pylori at bacterium/cell ratio of 300:1 for 30 minutes. To determine the transfection efficiency of PAR-2 AS ODN or S ODN, the level of PAR-2 was determined in the transfected cells cultured in the presence of H. pylori at bacterium/cell ratio of 300:1 for 2 hours.

Determination of cell viability and DNA fragmentation

AGS cells were cultured in the presence of H. pylori at a bacterium/cell ratio of 150:1 or 300:1 for 24 hours. Viable cells were determined by trypan blue exclusion test (0.2% trypan blue). DNA fragmentation was determined by the amount of oligonucleosome-bound DNA in the cell lysates using a sandwich ELISA (Cell Death Detection ELISAplus kit; Boehringer-Mannheim). The relative increase in oligonucleosome-bound DNA was determined at 405 nm and expressed as an enrichment factor.

Treatment with ODNs using cationic liposome

Single-stranded oligonuceltides (ODNs) were produced commercially (GIBCO BRL, Rockville, MD, USA). ODNs were phosphorothioate-modified to reduce intracellular nuclease digestion. Antisense (AS) and sense (S) ODNs targeted the ATG start codon of the human PAR-2 mRNA [GenBank: AY336105.1]. The sequence of the PAR-2 AS ODN was 5'TCCGCATCCTCCTGGAA3'. The sequence of PAR-2 S ODN was 5'TTCCAGGAGGATGCGGA3'. AGS cells were transfected with ODNs using a cationic liposome, a commercially available transfection-reagent DOTAP (N-[1-(2,3-dioleoyloxy) propyl]-N, N, Ntrimethyl ammonium methylsulfate) (Boehringer-Mannheim, Pentzberg, Germany) to improve stability and intracellular delivery of ODNs. When DOTAP was employed, the appropriate amount of ODNs were incubated with DOTAP (15 μl/ml) to achieve the respective final concentration of the ODNs to 0.5 μM at 37°C for 15 min. The cells were treated with the mixture and then incubated for 24 hours. After medium was changed with antibiotic-free medium, the transfected cells were cultured in the presence of H. pylori.

Western blot analysis

One hundred μg of whole cell extracts was loaded per lane, separated by SDS-polyacrylamide gel electrophoresis (PAGE) under reducing conditions, and transferred onto Hybond-PVDF membranes (Amersham Inc., Arlington Heights, IL, USA) by electroblotting. The transfer of protein and equality of loading in all lanes was verified using reversible staining with Ponceau S. Membranes were blocked using 5% nonfat dry milk. PAR-2, ERK1/2, p38, and JNK1/2 were detected by incubation of blots with specific polyclonal antibodies, followed by sheep anti-mouse secondary antibody conjugated to horseradish peroxidase. The proteins were determined by enhanced chemiluminescence (Amersham) using exposure to BioMax MR film (Kodak).

Statistical analysis

Results are expressed as means ± standard error of four separate experiments. Analysis of variance (ANOVA) followed by Newman-Keul's test was used for statistical analysis. P< 0.05 was considered statistically significant

Results

Inhibition of PAR-2 expression augments H. pylori-induced cell death and DNA fragmentation in gastric epithelial cells

To investigate the relations of PAR-2 expression, cell death, and DNA fragmentation, cells were transfected with AS ODN for PAR-2 and cultured in the presence of H. pylori. As shown in figure 1, H. pylori induced the expression of PAR-2, which was inhibited in the cells transfected with PAR-2 AS ODN. Viable cell numbers were decreased by H. pylori with the number of bacterium infected to the cells (Figure 2A). Cell death of H. pylori-infected cells was augmented by transfection with PAR-2 AS ODN, compared with that of the cells transfected with S ODN or wild cells (non-transfected cells). Similarly, H. pylori-induced DNA fragmentations increased by transfection with PAR-2 AS ODN, compared with corresponding S ODN or wild cells (Figure 2B). These results suggest that H. pylori- induced expression of PAR-2 may have a protective role against apoptosis of gastric epithelial cells, determined by cell death and DNA fragmentation.
Figure 1
Figure 1

Transfection of AS ODN for PAR-2 inhibits the expressiongn of PAR-2 in H. pylori -infected AGS cells. AGS cells were transfected with PAR-2 AS ODN or S ODN for 24 hours and cultured in the absence or the presence of H. pylori at a bacterium/cells ratio of 300:1 for 2 hours. The levels of PAR-2 were determined by Western blot analysis using specific antibody for PAR-2. Actin served as a loading control. Wild, the cells without transfection; Transfected, the cells transfected with S ODN (S) or AS ODN (AS). None, the cells without transfection and cultured in the absence of H. pylori; H. pylori control, the cells without transfection and cultured in the presence of H. pylori.

Figure 2
Figure 2

Inhibition of PAR-2 expression augments H. pylori -induced cell death and DNA fragmentation in AGS cells. (A) AGS cells were transfected with PAR-2 AS ODN or S ODN for 24 hours and cultured in the absence or the presence of H. pylori at a bacterium/cells ratio of 150:1 or 300:1 for 24 hours. Viable cell numbers were determined by trypan blue exclusion test. The results represent mean ± SE of four different experiments. *P < 0.05 compared to the corresponding none (the cells cultured in the absence of H. pylori ). +P < 0.05 compared to the corresponding wild or PAR-2 S (wild cells or the cells transfected with S ODN and cultured in the presence of H. pylori at a bacterium/cells ratio of 150:1 or 300:1). (B) AGS cells were transfected with PAR-2 AS ODN or S ODN for 24 hours and cultured in the absence or the presence of H. pylori at a bacterium/cells ratio of 300:1 for 24 hours. DNA fragmentation was determined by the amount of oligonucleosome-bound DNA in the cell lysates. The relative increase in oligonucleosome-bound DNA was determined at 405 nm and expressed as an enrichment factor. The results represent mean ± SE of four different experiments. *P < 0.05 compared to none control (the cells without transfection and cultured in the absence of H. pylori). +P < 0.05 compared to wild H. pylori control (the cells without transfection and cultured in the presence of H. pylori). Wild, the cells without transfection; Transfected, the cells transfected with S ODN (S) or AS ODN (AS).

Inhibition of PAR-2 expression suppresses H. pylori-induced activation of MAPK in gastric epithelial cells

To determine the role of PAR-2 on the activation of MAPK, the activation of three major MAPK involved in cell proliferation and apoptosis were assessed by Western blotting of phospho-specific and total forms of MAPK (p38, ERK1/2, JNK1/2). As shown figure 3, levels of phospho-specific forms of p38, ERK1/2, and JNK1/2 increased by H. pylori in AGS cells. H. pylori did not affect total forms of p38, ERK1/2, and JNK1/2 in AGS cells. H. pylori-induced activation of MAPK was inhibited in the cells transfected with PAR-2 AS ODN, but that was not affected in the cells transfected with S ODN. These results demonstrate that both H. pylori-induced expression of PAR-2 and activation of MAPK may be related to cell viability of gastric epithelial cells after H. pylori infection.
Figure 3
Figure 3

Inhibition of PAR-2 expression suppresses H. pylori -induced activation of MAPK in gastric epithelial cells. AGS cells were transfected with PAR-2 AS ODN or S ODN for 24 hours and cultured in the absence or the presence of H. pylori at a bacterium/cells ratio of 300:1 for 30 minutes. The levels of phospho-specific and total forms of MAPK (p38, ERK1/2, JNK1/2) were determined by Western blotting using specific antibodies for the indicated proteins. Wild, the cells without transfection; Transfected, the cells transfected with S ODN (S) or AS ODN (AS). None, the cells without treatment and cultured in the absence of H. pylori; H. pylori control, the cells without treatment and cultured in the presence of H. pylori.

Soybean trypsin inhibitor (SBTI) augments H. pylori-induced cell death and DNA fragmentation in gastric epithelial cells concentration-dependently

Since PAR-2 is activated by trypsin [14, 15], SBTI was treated to the cells and cultured in the presence of H. pylori to suppress the activity of PAR-2. Viable cell numbers were decreased by H. pylori with the number of bacterium infected to the cells (Figure 4A). Cell death of H. pylori-infected cells was augmented by treatment of SBTI concentration-dependently. H. pylori-induced DNA fragmentations increased by treatment of 0.5 μM of SBTI (Figure 4B). These results suggest that inhibition of trypsin activity, which induces the suppression of PAR-2 activity, augments H. pylori- induced cell death and DNA fragmentation.
Figure 4
Figure 4

Soybean trypsin inhibitor (SBTI) augments H. pylori -induced cell death and DNA fragmentation in gastric epithelial cells concentration-dependently. (A) AGS cells were treated with SBTI (0.2 μM, 0.5 μM) and cultured in the absence or the presence of H. pylori at a bacterium/cells ratio of 150: or 300:1 for 24 hours. Viable cell numbers were determined by trypan blue exclusion test. The results represent mean ± SE of four different experiments. *P < 0.05 compared to none (the cells without treatment and cultured in the absence of H. pylori). +P < 0.05 compared to the corresponding none (the cells without treatment and cultured in the presence of H. pylori at a bacterium/cells ratio of 150: or 300:1). (B) AGS cells were treated with SBTI (0.5 μM) and cultured in the absence or the presence of H. pylori at a bacterium/cells ratio of 300:1 for 24 hours. DNA fragmentation was determined by the amount of oligonucleosome-bound DNA in the cell lysates. The relative increase in oligonucleosome-bound DNA was determined at 405 nm and expressed as an enrichment factor. The results represent mean ± SE of four different experiments. *P < 0.05 compared to none control (the cells without treatment and cultured in the absence of H. pylori). +P < 0.05 compared to H. pylori control (the cells without treatment and cultured in the presence of H. pylori).

Soybean trypsin inhibitor (SBTI) suppresses H. pylori-induced activation of MAPK in gastric epithelial cells

H. pylori -induced increases in phospho-specific forms of p38, ERK1/2, and JNK1/2 were inhibited by treatment by treatment of SBTI in AGS cells concentration-dependently (figure 5). As shown figure 3, H. pylori did not affect total forms of p38, ERK1/2, and JNK1/2 in AGS cells, which was not affected by treatment of SBTI (figure 5). These results suggest that PAR2, which may be activated by trypsin, may be involved in the activation of MAPK in H. pylori-infected gastric epithelial cells.
Figure 5
Figure 5

Soybean trypsin inhibitor (SBTI) suppresses H. pylori -induced activation of MAPK in gastric epithelial cells. AGS cells were treated with SBTI and cultured in the absence or the presence of H. pylori at a bacterium/cells ratio of 300:1 for 30 minutes. The levels of phospho-specific and total forms of MAPK (p38, ERK1/2, JNK1/2) were determined by Western blotting using specific antibodies for the indicated proteins. None, the cells without treatment and cultured in the absence of H. pylori; H. pylori control, the cells without treatment and cultured in the presence of H. pylori.

Discussion

In the present study, we found that H. pylori-induced cell death and DNA fragmentation were augmented by inhibition of PAR-2 expression using PAR-2 AS ODN in AGS cells. Additionally, inhibition of PAR-2 activity using trypsin inhibitor increased cell death and DNA fragmentation in H. pylori-infected AGS cells. These results demonstrate that the expression and the activation of PAR-2 induced by H. pylori may prevent apoptotic cell death in gastric epithelial cells.

Previously we demonstrated that H. pylori induced the expression and activation of PAR-2, which mediates the expression of COX-2 and integrins in gastric epithelial cells [21, 22]. Trypsin activated PAR-2, which mediated the proliferation of various cells including pancreatic and gastric cancer cells, and smooth muscle cells [23–25]. Additionally, activation of PAR-2 by agonist or activating peptide protects astrocytes and neutrophils against apoptotic cell death [26, 27]. These studies support the present results showing that H. pylori-induced expression of PAR-2 may protect gastric epithelial cells from cell death and DNA fragmentation.

Furthermore, we here found that activation of MAPK was mediated by PAR-2 in H. pylori-infected gastric epithelial cells. This result is consistent with the previous studies showing that the activation of PAR-2 is related to the activation of MAPK in mouse tracheal and bronchial smooth muscle [16, 17]. The MAPK signaling pathways play essential roles in cell proliferation and apoptosis [18, 19]. MAPK activated by H. pylori infection is involved in apoptosis of gastric epithelial cells [28–30]. Ding et al. [28] demonstrated that inhibition on the activation of ERK1/2, JNK1/2 or p38 by treatment of the chemical inhibitor increased H. pylori-induced apoptosis in gastric epithelial cells. These studies suggest that PAR-2 activation induced by H. pylori may protect gastric epithelial cells from apoptosis by the activation of MAPK. In contrast, inhibition of p38 by a specific inhibitor SB203580 decreased apoptosis while ERK1/2 inhibition by a specific inhibitor PD98059 resulted in an increase of apoptosis in H. pylori-infected gastric epithelial cells [29]. Further studies should be performed to investigate the role of PAR-2 on the activation of specific MAPK and its relation to the expression of apoptotic genes in H. pylori-infected gastric epithelial cells. Recently it was reported that other PARs such as PAR-1 and PAR-4 protect cell apoptosis through ERK or JNK signaling pathway [30–34]. Therefore, the expression and activation of PAR-2 induced by H. pylori may rescue gastric epithelial cells from apoptosis via MAPK signaling.

Other possible protective proteins other than PARs, antiapoptotic proteins such as inhibitors-of-apoptosis-proteins (IAPs) were induced by NF-κB activation and protected the cells from apoptosis induced by the wild-type H. pylori containing virulence factor cytotoxin-associated gene (cagA) [35]. Molecular chaperone heat shock protein 70 protected gastric injury against monochloramine which is generated by neutrophil-derived hypochlorous acid and H pylori urease-induced ammonia [36]. H. pylori infection upregulated gastric mucosal peroxiredoxin (Prx) I expression, and further, that Prx I played an important role in gastric mucosal protection against oxidative injury induced by H. pylori infection [37]. Recently, it was found that the disturbances in gastric mucosal NO generation system caused by H. pylori resulted from the inducible nitric oxide synthase (iNOS). They demonstrated that peptide hormone ghrelin protected gastric mucosa from H. pylori-induced proapoptotic events by a decrease in S-nitrosylation of constitutive nitric oxide synthase (cNOS) [38].

Regarding virulence factors of H. pylori, cagA and vacuolating cytotoxin A (vacA) are reported to contribute to gastric cancer incidence [39, 40]. Since H. pylori in Korean isolates, HP99 used in the present study, contains both cagA and vacA [41], the present result may explain the possible mechanism of H. pylori-induced gastric carcinogenesis. Further study should be performed to investigate the mechanism of gastric carcinogenesis involving PAR-2-associated prevention against apoptosis of gastric epithelial cells infected with H. pylori containing different isotypes of virulence factors.

Conclusion

PAR-2, whose expression is induced by H. pylori, may prevent cell death and DNA fragmentation with the activation of MAPK in gastric epithelial cells. These results demonstrate a novel mechanism of protection against apoptotic cell death by PAR-2 in H. pylori-infected gastric epithelial cells.

Abbreviations

AS: 

antisense

MAPK: 

mitogen-activated protein kinase

ODN: 

oligonucleotide

PAR: 

protease-activated receptor

S: 

sense

SBTI: 

soybean trypsin inhibitor

Declarations

Acknowledgements

This work was supported by a Korea Research Foundation Grant funded by the Korean Government (MOEHRD) (KRF-2006-353-E00008) (to J. W. Lim) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2010-0001669, 2010-0002916) (to H. Kim). H. Kim is grateful to the Brain Korea 21 Project, Yonsei University.

Authors’ Affiliations

(1)
Department of Food and Nutrition, Brain Korea 21 Project, College of Human Ecology, Yonsei University, Seoul, 120-749, Korea

References

  1. Negrini R, Savio A, Poiesi C, Appelmelk BJ, Buffoli F, Paterlini A, Cesari P, Graffeo M, Vaira D, Franzin G: Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology. 1996, 111: 655-665. 10.1053/gast.1996.v111.pm8780570.PubMedView ArticleGoogle Scholar
  2. Parsonnet J, Friedman GD, Vandersteen DP: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991, 325: 1127-1131. 10.1056/NEJM199110173251603.PubMedView ArticleGoogle Scholar
  3. Xia HH, Talley NJ: Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implications in gastric carcinogenesis. Am J Gastroenterol. 2001, 96: 16-26. 10.1016/S0002-9270(00)02240-1.PubMedView ArticleGoogle Scholar
  4. Hall PA, Coates PJ, Ansari B, Hopwood D: Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci. 1994, 107: 3569-3577.PubMedGoogle Scholar
  5. Jones NL, Shannon PT, Cutz E, Yeger H, Sherman PM: Increase in proliferation and apoptosis of gastric epithelial cells early in the natural history of Helicobacter pylori infection. Am J Pathol. 1997, 151: 1695-1703.PubMedPubMed CentralGoogle Scholar
  6. Moss SF, Calam J, Agarwal B, Wang S, Holt PR: Induction of gastric epithelial apoptosis by Helicobacter pylori. Gut. 1996, 738: 498-501. 10.1136/gut.38.4.498.View ArticleGoogle Scholar
  7. Peek RM, Blaser MJ, Mays DJ, Forsyth MH, Cover TL, Song SY, Krishna U, Pietenpol JA: Helicobacter pylori strain-specific genotypes and modulation of the gastric epithelial cell cycle. Cancer Res. 1999, 59: 6124-6131.PubMedGoogle Scholar
  8. Rudi J, Kuck D, Strand S, von Herbay A, Mariani SM, Krammer PH, Galle PR, Stremmel W: Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis. J Clin Investig. 1998, 102: 1506-1514. 10.1172/JCI2808.PubMedPubMed CentralView ArticleGoogle Scholar
  9. Konturek PC, Pierzchalski P, Konturek SJ, Meixner H, Faller G, Kirchner T, Hahn EG: Helicobacter pylori induces apoptosis in gastric mucosa through an upregulation of Bax expression in humans. Scand J Gastroenterol. 1999, 34: 375-383. 10.1080/003655299750026380.PubMedView ArticleGoogle Scholar
  10. Bhattacharyya A, Chattopadhyay R, Burnette BR, Cross JV, Mitra S, Ernst PB, Bhakat KK, Crowe SE: Acetylation of apurinic/apyrimidinic endonuclease-1 regulates Helicobacter pylori-mediated gastric epithelial cell apoptosis. Gastroenterology. 2009, 136: 2258-2269. 10.1053/j.gastro.2009.02.014.PubMedView ArticleGoogle Scholar
  11. Kim H: Oxidative stress in Helicobacter pylori-induced gastric cell injury. Inflammopharmacology. Inflammopharmacology. 2005, 13: 63-74. 10.1163/156856005774423962.PubMedView ArticleGoogle Scholar
  12. Seo JH, Lim JW, Kim H, Kim KH: Helicobacter pylori in a Korean isolate activates mitogen-activated protein kinases, AP-1, and NF-kB and induces chemokine expression in gastric epithelial AGS cells. Lab Invest. 2004, 84: 49-62. 10.1038/labinvest.3700010.PubMedView ArticleGoogle Scholar
  13. Choi IJ, Kim JS, Kim JM, Jung HC, Song IS: Effect of inhibition of extracellular signal-regulated kinase 1 and 2 pathway on apoptosis and bcl-2 expression in Helicobacter pylori-infected AGS cells. Infect Immun. 2003, 71: 830-837. 10.1128/IAI.71.2.830-837.2003.PubMedPubMed CentralView ArticleGoogle Scholar
  14. Hollenberg MD, Compton SJ: International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev. 2002, 54: 203-217. 10.1124/pr.54.2.203.PubMedView ArticleGoogle Scholar
  15. Ossovskaya VS, Bunnett NM: Protease-activated receptors: contribution to physiology and disease. Physiol Rev. 2004, 84: 579-621. 10.1152/physrev.00028.2003.PubMedView ArticleGoogle Scholar
  16. Coelho AM, Ossovskaya V, Bunnett NW: Proteinase-activated receptor-2: physiological and pathophysiological roles. Curr Med Chem Cardiovasc Hematol Agents. 2003, 1: 61-72. 10.2174/1568016033356715.PubMedView ArticleGoogle Scholar
  17. Kawabata A, Kubo S, Ishiki T, Kawao N, Sekiguchi F, Kuroda R, Hollenberg MD, Kanke T, Saito N: Proteinase-activated receptor-2-mediated relaxation in mouse tracheal and bronchial smooth muscle: signal transduction mechanisms and distinct agonist sensitivity. J Pharmacol Exp Ther. 2004, 311: 402-410. 10.1124/jpet.104.068387.PubMedView ArticleGoogle Scholar
  18. Chinni C, de Niese MR, Jenkins AL, Pike RN, Bottomley SP, Mackie EJ: Protease-activated receptor-2 mediates proliferative responses in skeletal myoblasts. J Cell Sci. 2000, 113 (Pt 24): 4427-4433.PubMedGoogle Scholar
  19. Shpacovitch VM, Seeliger S, Huber-Lang M, Balkow S, Feld M, Hollenberg MD, Sarma VJ, Ward PA, Strey A, Gerke V, Sommerhoff CP, Vergnolle N, Steinhoff M: Agonists of proteinase-activated receptor-2 affect transendothelial migration and apoptosis of human neutrophils. Exp Dermatol. 2007, 16: 799-806. 10.1111/j.1600-0625.2007.00605.x.PubMedView ArticleGoogle Scholar
  20. Wang Y, Luo W, Reiser G: Proteinase-activated receptor-1 and -2 induce the release of chemokine GRO/CINC-1 from rat astrocytes via differential activation of JNK isoforms, evoking multiple protective pathways in brain. Biochem J. 2007, 401: 65-78. 10.1042/BJ20060732.PubMedPubMed CentralView ArticleGoogle Scholar
  21. Seo JH, Kim KH, Kim H: Role of proteinase-activated receptor-2 on cyclooxygenase-2 expression in H. pylori-infected gastric epithelial cells. Ann NY Acad Sci. 2007, 1096: 29-36. 10.1196/annals.1397.067.PubMedView ArticleGoogle Scholar
  22. Seo JH, Lim JW, Yoon JH, Kim KH: Proteinase-activated receptor-2 mediates the expression of integrin alpha5 and beta1 in Helicobacter pylori-infected gastric epithelial AGS cells. Digestion. 2009, 80 (1): 40-9. 10.1159/000216353.PubMedView ArticleGoogle Scholar
  23. Yoshida N, Yoshikawa T: Basic and translational research on proteinase-activated receptors: implication of proteinase/proteinase-activated receptor in gastrointestinal inflammation. J Pharmacol Sci. 2008, 108: 415-21. 10.1254/jphs.08R31FM.PubMedView ArticleGoogle Scholar
  24. Hirano J, Kanaide H: Role of protease-activated receptors in the vascular system. J Atheroscler Thromb. 2003, 10: 211-225.PubMedView ArticleGoogle Scholar
  25. Caruso R, Pallone F, Fina D, Gioia V, Peluso I, Caprioli F, Stolfi C, Perfetti A, Spagnoli LG, Palmieri G, Macdonald TT, Monteleone G: Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am J Pathol. 2006, 169: 268-278. 10.2353/ajpath.2006.050841.PubMedPubMed CentralView ArticleGoogle Scholar
  26. Wang Y, Luo W, Reiser G: Activation of protease-activated receptors in astrocytes evokes a novel neuroprotective pathway through release of chemokines of the growth-regulated oncogene/cytokine-induced neutrophil chemoattractant family. Eur J Neurosci. 2007, 26: 3159-3168. 10.1111/j.1460-9568.2007.05938.x.PubMedView ArticleGoogle Scholar
  27. Shpacovitch VM, Seeliger S, Huber-Lang M, Balkow S, Feld M, Hollenberg MD, Sarma VJ, Ward PA, Strey A, Gerke V, Sommerhoff CP, Vergnolle N, Steinhoff M: Agonists of proteinase-activated receptor-2 affect transendothelial migration and apoptosis of human neutrophils. Exp Dermatol. 2007, 16: 799-806. 10.1111/j.1600-0625.2007.00605.x.PubMedView ArticleGoogle Scholar
  28. Ding SZ, Smith MF, Goldberg JB: Helicobacter pylori and mitogen-activated protein kinases regulate the cell cycle, proliferation and apoptosis in gastric epithelial cells. J Gastroenterol Hepatol. 2008, 23 (7 Pt 2): e67-78. 10.1111/j.1440-1746.2007.04912.x.PubMedView ArticleGoogle Scholar
  29. Choi IJ, Kim JS, Kim JM, Jung HC, Song IS: Effect of inhibition of extracellular signal-regulated kinase 1 and 2 pathway on apoptosis and bcl-2 expression in Helicobacter pylori-infected AGS cells. Infect Immun. 2003, 71: 830-837. 10.1128/IAI.71.2.830-837.2003.PubMedPubMed CentralView ArticleGoogle Scholar
  30. Suzuki T, Moraes TJ, Vachon E, Ginzberg HH, Huang TT, Matthay MA, Hollenberg MD, Marshall J, McCulloch CA, Abreu MT, Chow CW, Downey GP: Proteinase-activated receptor-1 mediates elastase-induced apoptosis of human lung epithelial cells. Am J Respir Cell Mol Biol. 2005, 33: 231-247. 10.1165/rcmb.2005-0109OC.PubMedPubMed CentralView ArticleGoogle Scholar
  31. Chalmers CJ, Balmanno K, Hadfield K, Ley R, Cook SJ: Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1. Biochem J. 2003, 375 (Pt 1): 99-109. 10.1042/BJ20030346.PubMedPubMed CentralView ArticleGoogle Scholar
  32. Borensztajn KS, Bijlsma MF, Groot AP, Brüggemann LW, Versteeg HH, Reitsma PH, Peppelenbosch MP, Spek CA: Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation. Exp Cell Res. 2007, 313: 2622-2633. 10.1016/j.yexcr.2007.04.014.PubMedView ArticleGoogle Scholar
  33. Wang Y, Luo W, Stricker R, Reiser G: Protease-activated receptor-1 protects rat astrocytes from apoptotic cell death via JNK-mediated release of the chemokine GRO/CINC-1. J Neurochem. 2006, 98: 1046-1060. 10.1111/j.1471-4159.2006.03950.x.PubMedView ArticleGoogle Scholar
  34. Garcia-Cao I, Lafuente MJ, Criado LM, Diaz-Meco MT, Serrano M, Moscat J: Genetic inactivation of PAR4 results in hyperactivation of NF-κB and impairment of JNK and p38. EMBO Rep. 2003, 4: 307-312. 10.1038/sj.embor.embor769.PubMedPubMed CentralView ArticleGoogle Scholar
  35. Maeda S, Yoshida H, Mitsuno Y, Hirata Y, Ogura K, Shiratori Y, Omata M: Analysis of apoptotic and antiapoptotic signalling pathways induced by Helicobacter pylori. Mol Pathol. 2002, 55 (5): 286-293. 10.1136/mp.55.5.286.PubMedPubMed CentralView ArticleGoogle Scholar
  36. Oyake J, Otaka M, Matsuhashi T, Jin M, Odashima M, Komatsu K, Wada I, Horikawa Y, Ohba R, Hatakeyama N, Itoh H, Watanabe S: Over-expression of 70-kDa heat shock protein confers protection against monochloramine-induced gastric mucosal cell injury. Sci. 2006, 79 (3): 300-305.Google Scholar
  37. Sato D, Yanaka A, Shibahara T, Matsui H, Nakahara A, Yanagawa T, Warabi E, Ishii T, Hyodo I: Peroxiredoxin I protects gastric mucosa from oxidative injury induced by H. pylori infection. J Gastroenterol Hepatol. 2008, 23 (4): 652-659. 10.1111/j.1440-1746.2007.05217.x.PubMedView ArticleGoogle Scholar
  38. Slomiany BL, Slomiany A: Role of constitutive nitric oxide synthase S-nitrosylation in Helicobacter pylori-induced gastric mucosal cell apoptosis: effect of ghrelin. Inflammopharmacology. 2010,Google Scholar
  39. Labigne A, de Reuse H: Determinants of Helicobacter pylori pathogenicity. Infect Agents Dis. 1996, 5: 191-202.PubMedGoogle Scholar
  40. Mobley HL: Defining Helicobacter pylori as a pathogen: strain heterogenicity and virulence. Am J Med. 1997, 100: 2S-11S.View ArticleGoogle Scholar
  41. Miehlke S, Kibler K, Kim JG, Figura N, Small SM, Graham DY, Go MF: Allelic variation in the cagA gene of Helicobacter pylori obtained from Korea compared to the United States. Am J Gastroenterol. 1996, 91: 1322-1325.PubMedGoogle Scholar

Copyright

© Lim and Kim; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

Journal of Translational Medicine

ISSN: 1479-5876

Contact us